To The Moon

Congrats to all the $Hims & Hers Health Inc.(HIMS)$   holders — the stock just jumped 40% after hours! 🚀

Looks like Novo Nordisk (Novo Nordisk (NVO)) may have dropped the lawsuit and decided to partner with HIMS, selling Novo-branded GLP-1 receptor agonists.

$NVO Novo Nordisk on Danish newspaper Børsen:

"We are in ongoing dialogue with companies that can help improve patient access to regulatory approved medicines for people living with chronic diseases.

These discussions are continuous, and we will provide further updates if or when final decisions or agreements are reached."

No confirmation yet from the $Novo-Nordisk A/S(NVO)$   team on that Bloomberg report yesterday. Although they didn’t deny the rumors.

Even more interesting… HIMS is about 39% shorted. 👀

That means if the news is real and momentum continues, short sellers may have to rush to cover.

Muthu Boy can already smell the possibility of a short squeeze cooking in the pan… 🍳

$HIMS is continuing to expand its global footprint, leveraging Zava in Europe and Eucalyptus across Canada, Australia, and Japan.

The $HIMS CFO also reaffirmed that the company remains on track to achieve its 2030 targets of $6.5B in revenue and $1.3B in adjusted EBITDA.

With the stock heavily shorted, Monday could potentially set the stage for one of the biggest short squeezes in history. 🚀📈

Some traders are even whispering that if a squeeze happens, the stock could go parabolic toward $100. 📈🔥

Meanwhile, Muthu has her own dream:

If everyone takes GLP-1 and doesn’t get fat… maybe they can eat more prata without guilt.

Please support Prata Boy’s shop.

More GLP-1, more prata. Everybody wins. 🫓😄

@Tiger_comments  @Daily_Discussion  @TigerStars  @TigerObserver  @TigerPM  @Tiger_comments